Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16,090 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparison of site-reported and core laboratory-reported creatine kinase-MB values in non-ST-segment elevation acute coronary syndrome (from the international trial SYNERGY).
Linefsky JP, Lin M, Pieper KS, Reist CJ, Berdan LG, Antman EM, Goodman SG, French JK, Guneri S, Roe MT, Newby LK, Harrington RA, Ferguson JJ, Califf RM, Mahaffey KW. Linefsky JP, et al. Among authors: lin m. Am J Cardiol. 2009 Nov 15;104(10):1330-5. doi: 10.1016/j.amjcard.2009.06.056. Epub 2009 Sep 25. Am J Cardiol. 2009. PMID: 19892046 Clinical Trial.
First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity.
Dyke CK, Steinhubl SR, Kleiman NS, Cannon RO, Aberle LG, Lin M, Myles SK, Melloni C, Harrington RA, Alexander JH, Becker RC, Rusconi CP. Dyke CK, et al. Among authors: lin m. Circulation. 2006 Dec 5;114(23):2490-7. doi: 10.1161/CIRCULATIONAHA.106.668434. Epub 2006 Nov 13. Circulation. 2006. PMID: 17101847 Clinical Trial.
Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease.
Chan MY, Cohen MG, Dyke CK, Myles SK, Aberle LG, Lin M, Walder J, Steinhubl SR, Gilchrist IC, Kleiman NS, Vorchheimer DA, Chronos N, Melloni C, Alexander JH, Harrington RA, Tonkens RM, Becker RC, Rusconi CP. Chan MY, et al. Among authors: lin m. Circulation. 2008 Jun 3;117(22):2865-74. doi: 10.1161/CIRCULATIONAHA.107.745687. Epub 2008 May 27. Circulation. 2008. PMID: 18506005 Clinical Trial.
Edoxaban Plus Aspirin vs Dual Antiplatelet Therapy in Endovascular Treatment of Patients With Peripheral Artery Disease: Results of the ePAD Trial.
Moll F, Baumgartner I, Jaff M, Nwachuku C, Tangelder M, Ansel G, Adams G, Zeller T, Rundback J, Grosso M, Lin M, Mercur MF, Minar E; ePAD Investigators. Moll F, et al. Among authors: lin m. J Endovasc Ther. 2018 Apr;25(2):158-168. doi: 10.1177/1526602818760488. J Endovasc Ther. 2018. PMID: 29552984 Free PMC article. Clinical Trial.
Genetic variants in UNC93B1 predispose to childhood-onset systemic lupus erythematosus.
Al-Azab M, Idiiatullina E, Liu Z, Lin M, Hrovat-Schaale K, Xian H, Zhu J, Yang M, Lu B, Zhao Z, Liu Y, Chang J, Li X, Guo C, Liu Y, Wu Q, Chen J, Lan C, Zeng P, Cui J, Gao X, Zhou W, Zhang Y, Zhang Y, Masters SL. Al-Azab M, et al. Among authors: lin m. Nat Immunol. 2024 Jun;25(6):969-980. doi: 10.1038/s41590-024-01846-5. Epub 2024 Jun 3. Nat Immunol. 2024. PMID: 38831104
16,090 results
You have reached the last available page of results. Please see the User Guide for more information.